Acromegaly Market, Size, Share, Trends, Epidemiology Forecast till 2030

Acromegaly Market

DelveInsight’s ‘Acromegaly Market Insights, Epidemiology, and Market Forecast–2030 report deliver an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Acromegaly is a rare and chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma.

Various targets for treatment have been used in the past but the current consensus is to aim for a growth hormone level of less than 1 µg/l after an oral glucose tolerance test and a normal IGF-1 level for age and sex. There is also a general agreement that a basal growth hormone level below 2.5 µg/L is an acceptable target to consider the patient as cured. Tumor excision is generally the first line of treatment usually done via the trans-sphenoidal route to reduce the GH and IGF-I concentrations in the patients with Acromegaly. The goal of surgery is to balance maximal tumors mass resection while preserving the normal pituitary secretory function.

The US FDA approved therapies for the treatment of acromegaly include Somatuline Depot (lanreotide acetate) injection, Somavert (pegvisomant), Sandostatin LAR Depot, and Signifor LAR (pasireotide). Somatuline Depot (lanreotide acetate), Sandostatin LAR Depot (octreotide acetate), and Signifor LAR (pasireotide) are SSA analogs and Somavert (pegvisomant) is a GH antagonist.

Acromegaly market size in 7MM was USD 956.96 Million in 2017.

Acromegaly Market Drivers

  • Robust pipeline
  • Increase in Prevalence
  • More efficacious mono and combination therapies

Acromegaly Market Barriers

  • Economic burden
  • Low disease awareness and delay in diagnosis
  • No standard cure available

Scope of the Report

  • The report covers the descriptive overview of Acromegaly, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Acromegaly epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acromegaly is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Acromegaly market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acromegaly market.

Request for sample pages
Table of contents

 

1. Key Insights

2. Executive Summary

3. Acromegaly Market Overview at a Glance

3.1. Market (%) Distribution of Acromegaly in 2017

3.2. Market (%) Distribution of Acromegaly in 2030

4. Acromegaly (ACM): Disease Overview

4.1. Introduction

4.2. Signs and Symptoms

4.3. Classification of Pituitary Adenomas

4.4. Clinical Manifestations of Acromegaly

4.5. Etiology

4.6. Pathophysiology

4.7. Genetic Bases of Acromegaly

4.8. Pathogenesis

4.9. Diagnosis

4.9.1. Diagnosis Guidelines

4.9.2. Endocrine Society Clinical Practice Guideline-United Kingdom

4.9.3. American Association of Clinical Endocrinologists (AACE) – USA

5. Case Reports

5.1. Patients with Acromegaly Presenting with Colon Cancer: A Case Series

5.2. Case Report: Persistent Acromegaly – Effective Therapy with Lanreotide and Weekly Pegvisomant Injections

5.3. Management of acromegaly in pregnancy: Case report and literature review

5.4. A Case Report of an Elderly Patient with Acromegaly

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology

6.3. Total Prevalent Cases of Acromegaly in the 7MM

6.4. Total Diagnosed Cases of Acromegaly in the 7MM

7. United States Epidemiology

7.1. Total Prevalent Cases of Acromegaly in the United States

7.2. Diagnosed Cases of Acromegaly in the United States

7.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in the United States

7.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in the US

8. EU5 Epidemiology

8.1. Germany

8.1.1. Total Prevalent Cases of Acromegaly in Germany

8.1.2. Diagnosed Cases of Acromegaly in Germany

8.1.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Germany

8.1.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Germany

8.2. France

8.2.1. Total Prevalent Cases of Acromegaly in France

8.2.2. Diagnosed Cases of Acromegaly in France

8.2.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in France

8.2.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in France

8.3. Italy

8.3.1. Total Prevalent Cases of Acromegaly in Italy

8.3.2. Diagnosed Cases of Acromegaly in Italy

8.3.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Italy

8.3.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Italy

8.4. Spain

8.4.1. Total Prevalent Cases of Acromegaly in Spain

8.4.2. Diagnosed Cases of Acromegaly in Spain

8.4.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in Spain

8.4.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in Spain

8.5. United Kingdom

8.5.1. Total Prevalent Cases of Acromegaly in the United Kingdom

8.5.2. Diagnosed Cases of Acromegaly in the United Kingdom

8.5.3. Origin Specific Diagnosed Prevalent Cases of Acromegaly in the United Kingdom

8.5.4. Diagnosed Cases of Acromegaly Based on Type of Adenomas in the United Kingdom

9. Japan Epidemiology

9.1. Total Prevalent Cases of Acromegaly in Japan

9.2. Diagnosed Cases of Acromegaly in Japan

9.3. Origin-Based Diagnosed Prevalent Cases of Acromegaly in Japan

9.4. Diagnosed Cases of Acromegaly Based on Types of Adenomas in Japan

10. Treatment

10.1. Biomarkers of Acromegaly

10.2. Treatment Guidelines

10.2.1. American Association of Clinical Endocrinologists (AACE) – U.S.A.

10.2.2. Endocrine Society Clinical Practice Guideline-United Kingdom

11. Unmet Needs

12. Marketed Drug

12.1. Somatuline Depot (lanreotide acetate): Ipsen Biopharmaceuticals

12.1.1. Drug Description

12.1.2. Mechanism of Action

12.1.3. Regulatory Milestones

12.1.4. Advantages and Disadvantages

12.1.5. Clinical Development

12.1.6. Clinical Trials Information

12.1.7. Safety and Efficacy

12.1.8. Product Profile

12.2. Somavert (Pegvisomant): Pharmacia & Upjohn/Pfizer

12.2.1. Drug Description

12.2.2. Mechanism of Action

12.2.3. Regulatory Milestones

12.2.4. Clinical Development

12.2.5. Clinical Trials Information

12.2.6. Safety and Efficacy

12.2.7. Advantages and Disadvantages

12.2.8. Product Profile

12.3. Sandostatin LAR Depot: Novartis Pharmaceuticals

12.3.1. Drug Description

12.3.2. Mechanism of Action

12.3.3. Regulatory Milestones

12.3.4. Clinical Development

12.3.5. Clinical Trials Information

12.3.6. Safety and Efficacy

12.3.7. Advantages & Disadvantages

12.3.8. Product Profile

12.4. Signifor LAR (pasireotide): Novartis Pharmaceuticals

12.4.1. Drug Description

12.4.2. Mechanism of Action

12.4.3. Regulatory Milestones

12.4.4. Advantages & Disadvantages

12.4.5. Clinical Development

12.4.6. Clinical Trials Information

12.4.7. Safety and Efficacy

12.4.8. Product Profile

13. Key Cross Competition

14. Emerging Drugs

14.1. IONIS-GHR-LRx: Ionis Pharmaceuticals

14.1.1. Product Description

14.1.2. Other Developmental Activities

14.1.3. Clinical Development

14.1.4. Clinical Trials Information

14.1.5. Product Profile

14.2. Mycapssa (Octreotide Capsules): Chiasma Pharma

14.2.1. Product Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Development

14.2.4. Clinical Trials Information

14.2.5. Safety and Efficacy

14.2.6. Advantages and Disadvantages

14.2.7. Product Profile

14.3. ATL1103: Antisense Therapeutics

14.3.1. Product Description

14.3.2. Other Developmental Activities

14.3.3. Clinical Development

14.3.4. Clinical Trials Information

14.3.5. Safety and Efficacy

14.3.6. Product Profile

14.4. CAM2029: Camurus

14.4.1. Product Description

14.4.2. Other Developmental Activities

14.4.3. Clinical Development

14.4.4. Clinical Trials Information

14.4.5. Safety and Efficacy

14.4.6. Advantages and Disadvantages

14.4.7. Product Profile

14.5. GT-02037 (G-SRIF): GlyTech

14.5.1. Product Description

14.5.2. Other Developmental Activities

14.5.3. Clinical Development

14.5.4. Clinical Trials Informations

14.5.5. Product Profile

14.6. Veldoreotide (COR-005, DG3173): Strongbridge Biopharma

14.6.1. Product Description

14.6.2. Other Developmental Activities

14.6.3. Clinical Development

14.6.4. Clinical Trials Information

14.6.5. Safety and Efficacy

14.6.6. Advantages and Disadvantages

14.6.7. Product Profile

14.7. Paltusotine (CRN00808): Crinetics Pharmaceuticals

14.7.1. Product Description

14.7.2. Other Developmental Activities

14.7.3. Clinical Development

14.7.4. Clinical Trials Information

14.7.5. Safety and Efficacy

14.7.6. Advantages and Disadvantages

14.7.7. Product Profile

14.8. MTD201: Midatech

14.8.1. Product Description

14.8.2. Other Development Activities

14.8.3. Clinical Development

14.8.4. Clinical Trial information

14.8.5. Safety and Efficacy

14.8.6. Advantages and Disadvantages

14.8.7. Product Profile

14.9. Lanreotide PRF: Ipsen

14.9.1. Product Description

14.9.2. Clinical Development

14.9.3. Clinical Trial information

14.9.4. Safety and Efficacy

14.9.5. Advantages and Disadvantages

14.9.6. Product Profile

15. Acromegaly: Seven Major Market Analysis

15.1. Key Findings

15.2. Market Size of Acromegaly in the 7MM

15.3. Market Size of Acromegaly in the 7MM by Therapies

16. Market Outlook: The United States

16.1. The United States Market Size

16.1.1. Total Market size of Acromegaly

16.1.2. Market Size by Therapies

17. EU5: Market Outlook

17.1. Germany Market Size

17.1.1. Total Market Size of Acromegaly

17.1.2. Market Size by Therapies

17.2. France Market Size

17.2.1. Total Market Size of Acromegaly

17.2.2. Market Size by Therapies

17.3. Italy Market Size

17.3.1. Total Market size of Acromegaly

17.3.2. Market Size by Therapies

17.4. Spain Market Size

17.4.1. Total Market size of Acromegaly

17.4.2. Market Size by Therapies

17.5. The United Kingdom Market Size

17.5.1. Total Market size of Acromegaly

17.5.2. Market Size by Therapies

18. Japan: Market Outlook

18.1. Japan Market Size

18.2. Total Market size of Acromegaly

18.3. Market Size by Therapies

19. Market Drivers

20. Market Barriers

21. KOL Views

22. SWOT Analysis

23. Reimbursement and market access

24. Appendix

24.1. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight